Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Twist Bioscience Corporation filings document formal disclosures for a synthetic biology company with a silicon-based DNA synthesis platform. Form 8-K reports furnish quarterly and annual financial results, preliminary revenue information and business highlights tied to products and services such as synthetic DNA, NGS workflow tools and antibody discovery solutions.
The filing record also covers unregistered common stock issuances connected to licensing and technology-transfer arrangements, annual meeting voting results, director elections, auditor ratification, executive compensation votes, board appointments, committee service and director compensation. These disclosures address governance, capital structure and material events for TWST common stock.
Artisan Partners Asset Management and affiliated entities amended a Schedule 13G to report beneficial ownership of 6,217,213 shares of Twist Bioscience Corporation common stock, representing 10.1% of the class based on 01/27/2026. The filing states these shares were acquired on behalf of discretionary clients of Artisan Partners Limited Partnership.
Twist Bioscience Corporation filed an amended quarterly report mainly to correct typographical errors in officer certifications, while re-filing its full results for the quarter ended December 31, 2025.
Revenue rose to $103.7 million, up 16.9% from $88.7 million, driven by growth in both DNA synthesis and protein solutions and NGS applications. Gross margin improved to 52.0% from 48.3%, and operating loss narrowed slightly to $32.9 million. Net loss was $30.5 million, or $0.50 per share, compared with a $31.6 million loss, or $0.53 per share, a year earlier. The company used $24.8 million of cash in operating activities and ended the quarter with $197.9 million in cash, cash equivalents, and short-term investments, which management believes will fund operations for at least one year. As of January 27, 2026, there were 61,311,704 common shares outstanding.
Twist Bioscience Corp President and COO Patrick John Finn reported an open-market sale of 4,294 shares of common stock at an average price of $46.7098 per share. The transaction was a mandated “sell to cover” to satisfy tax withholding tied to vesting restricted stock units, not a discretionary trade. After this sale, Finn directly owns 284,129 Twist Bioscience shares, which includes shares acquired through the company’s employee stock purchase plan.
Twist Bioscience Corp's Chief Accounting Officer, Robert F. Werner, reported an open-market sale of 1,693 shares of common stock. The transaction occurred on February 23, 2026 at an average price of $46.7098 per share.
According to the footnote, these shares were sold to cover tax withholding obligations tied to the vesting of restricted stock units under the company’s equity incentive plans, and the sale was not a discretionary trade by the officer. After this sale, Werner directly holds 55,045 shares of Twist Bioscience common stock.
Twist Bioscience Corp Chief Financial Officer Adam Laponis reported an open-market sale of 2,085 shares of common stock of Twist Bioscience. The shares were sold at a weighted average price of $46.7098 per share to cover tax withholding obligations tied to vesting Restricted Stock Units, under a mandated “sell to cover” arrangement rather than at his discretion.
After this tax-related transaction, Laponis beneficially owns 128,291 shares of common stock, which include shares acquired under the company’s Employee Stock Purchase Plan in transactions exempt under Rule 16b-3(d) and Rule 16b-3(c).
Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported an automatic sale of 7,205 shares of common stock on February 23, 2026 at an average price of $46.7098 per share. The footnotes state this sale was required to cover tax withholding obligations related to vesting restricted stock units under the company’s equity plans and did not represent a discretionary trade. Following this transaction, she directly owned 863,052 common shares. The filing also lists several employee stock option grants and their vesting terms, which remain outstanding holdings rather than new transactions.
Twist Bioscience Corp executive Paula Green, SVP of Human Resources, reported an open-market sale of 1,465 shares of common stock at an average price of $46.7098 per share on February 23, 2026. According to the filing, these shares were sold to cover tax withholding obligations triggered by the vesting of Restricted Stock Units under the company’s equity incentive plans, and the sale was mandated as a “sell to cover” transaction rather than a discretionary trade. After this tax-related sale, she beneficially owns 125,336 shares, which include shares acquired through the company’s Employee Stock Purchase Plan in transactions exempt under Rule 16b-3(d) and Rule 16b-3(c).
Twist Bioscience Corp officer Dennis Cho reported an open-market sale of 844 shares of common stock at $46.7098 per share. According to the filing, the shares were sold to cover tax withholding owed on vesting restricted stock units under a mandatory “sell to cover” arrangement, rather than a discretionary trade. After this transaction, Cho directly held 138,682 shares.
TWST Form 144 reports a proposed sale of 7,205 common shares tied to restricted stock vesting on 02/20/2026.
The filing also records prior sales by Emily M. Leproust of $74,138.99 for 2,255 shares on 12/08/2025, $55,462.38 for 1,605 shares on 12/22/2025, and $232,924.08 for 5,001 shares on 02/03/2026.
Dennis H. Cho submitted a Form 144 notice relating to the proposed sale of 844 common shares tied to a restricted stock vesting event on 02/20/2026. The filing also lists recent dispositions during the prior three months: 398 shares on 12/08/2025, 324 shares on 12/22/2025, 1,099 shares on 02/03/2026, and 5,000 shares on 02/11/2026.